Completed NA INTERVENTIONAL 2-arm NCT03117894

PECS-2 for Breast Surgery

Regional Anesthesia for Breast Cancer Surgery, Effects on Postoperative Wellbeing and Disease Recurrence.

Sponsor: Umeå University

Conditions Anesthesia Anesthesia Morbidity Breast Neoplasm Female Regional Anesthesia Regional Anesthesia Morbidity

Interventions Arcoxia, 120 mg Betamethason 4 mg Morphine Ondansetron 4 mg Paracetamol 1,5 g Propofol Remifentanil 50 microg/ml Ropivacaine 5 mg/ml, 35 ml

Updated 8 times since 2017 Last updated: May 31, 2021 Started: May 23, 2017 Primary completion: Oct 22, 2020 Completion: Oct 22, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Anesthesia and Anesthesia Morbidity and is currently completed. Umeå University leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Sep 2021 — Jul 2024 [monthly]

Completed NA

Status: Recruiting → Completed
Jan 2021 — Sep 2021 [monthly]

Recruiting NA
Sep 2019 — Jan 2021 [monthly]

Recruiting NA

Status: Unknown Status → Recruiting

▶ Show 3 earlier versions

Jan 2019 — Sep 2019 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status
Jun 2018 — Jan 2019 [monthly]

Recruiting NA
Jun 2017 — Jun 2018 [monthly]

Recruiting NA

First recorded

May 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Umeå University

Data source: Umeå University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Östersund, Sweden